ReviewClinical therapeutics2021
Modifiable Risk Factors in Alzheimer Disease and Related Dementias: A Review.
Review in Clinical therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 3 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Pooled it
- Pooled it
- Association of inflammatory bowel disease and related medication exposure with risk of Alzheimer's disease: An updated meta-analysis.Frontiers in aging neuroscience · 2022Pooled it
- Prevalence, risk factors, and racial disparities in probable and possible dementia: the national health and aging trends study.The journal of prevention of Alzheimer's disease · 2026Article
- Is my loneliness killing me? Effects of loneliness and social isolation on transitions between cognitive status categories and death.Journal of personality and social psychology · 2026Article
- Article
- Neurodegenerative mortality among National Football League Players.EClinicalMedicine · 2026Article
- Crosstalk between death-associated protein kinase 1-regulated mechanisms and dysfunctions in alzheimer's disease.Molecular biology reports · 2026Review
- The relationship between alcohol use disorder, measures of cognitive decline, and Alzheimer disease biomarkers in middle aged and older adults.Alcohol, clinical & experimental research · 2026Article
- The role of stress, perceived discrimination, and skin tone on cognitive performance in Puerto Rican adults.Cultural diversity & ethnic minority psychology · 2026Article
- Unmasking the hidden catalyst: How infections trigger Alzheimer's disease.Journal of Alzheimer's disease : JAD · 2026Review
- Bloodwork-free Early Screening for Alzheimer's Disease via Comorbid Pattern Recognition in Electronic Health Records.Research square · 2026Article
- Long-term dementia risk in metabolic dysfunction-associated steatotic liver disease: a population-based study.Metabolic brain disease · 2026Article
- Complex atypical caregiving: navigating the margins of unique caregiver roles and burdens.Frontiers in psychology · 2026Article
- Electroencephalography for early Alzheimer's disease diagnosis: from advanced feature engineering to interpretable ai and clinical translation.Frontiers in psychiatry · 2026Review
- Unraveling disparities in county-level dementia diagnosis prevalence across the United States.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- A novel computational analysis integrating social determinants information from EHR and literature with Alzheimer's disease biological knowledge through large language models and knowledge graphs.Innovation in aging · 2025Article
- Qualitative study of stakeholder perspectives on dementia policy implementation in Macao: progress, challenges and future directions.BMJ open · 2025Article
- Article
- Mitochondrial haplogroups, but not heteroplasmy, are associated with midlife cognitive function.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
purposeAlthough Alzheimer disease and related dementias (ADRDs) have long been considered nonpreventable and even an inevitable consequence of aging, recent findings from longitudinal studies indicate a downtrend in age-adjusted incidence and prevalence of ADRDs in Western countries. This remarkable trend might be the result of improved management of so-called modifiable risk factors. The aim of this review is to present evidence of modifiable factors of ADRDs in a life-course approach.
methodsA PubMed database search was conducted between November and December 2020 to identify relevant studies evaluating the role of modifiable risk factors in the development of ADRDs. Key words (Alzheimer's disease and modifiable risk factors) were used and specific inclusion and exclusion criteria applied.
findingsThis review identifies modifiable factors for ADRDs divided into early-life, middle-life, and late-life risk factors, depending on the available window of preventive action. According to life course exposure, factors can be protective or deleterious for ADRDs that participate in the underlying pathophysiologic complexity of these diseases as well as the complexity for public health measures implementations. IMPLICATIONS: The available evidence derived from epidemiologic, preclinical, interventional studies suggest that modifiable risk factors for ADRDs offer opportunities for therapeutic and preventive actions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.